Aledade is a Healthcare Technology founded in 2014, currently valued at $3.5B. IPO Status: Pre-IPO. IPO Readiness Score: 68/100 (C+).
Aledade IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | Healthcare Technology |
| Stage | Series F |
| IPO Status | Pre-IPO |
| Valuation | $3.5B |
| Total Funding | $660M |
| Headquarters | Bethesda, MD |
| IPO Readiness Score | 68/100 |
| Founded | 2014 |
Track Aledade IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
Value-based care company empowering independent primary care physicians to succeed in value-based contracts.
Aledade is in the pre-IPO phase as of May 2026. The company has an IPO readiness score of 68/100, suggesting it may be 1–3 years from a public listing depending on market conditions and internal milestones. Pre-IPO companies at this stage typically evaluate market conditions, complete board appointments, and engage underwriters before initiating the formal S-1 filing process.
Aledade is valued at $3.5B based on the most recent private market data. The company has raised a total of $660M in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Accredited investors may be able to access Aledade pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Aledade has an IPO readiness score of 68/100 on TechStackIPO. A moderate readiness score suggests the company may be 2–4 years from IPO.
Aledade's last known private valuation is $3.5B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. Aledade has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
Aledade operates in the Healthcare Technology sector. TechStackIPO tracks multiple Healthcare Technology companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Aledade against other Healthcare Technology companies using TechStackIPO's comparison tool.
Aledade is at the Series F stage. The company has raised a total of $660M in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Aledade is headquartered in Bethesda, MD. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.